Evidinno Outcomes Research

What Evidinno Outcomes Research does

Evidinno Outcomes Research Inc. is a Vancouver-based healthcare research consulting firm serving pharmaceutical and biotechnology clients worldwide. Founded in 2017, the company delivers five integrated service lines: strategic consulting, literature reviews (systematic literature reviews and evidence synthesis), complex statistical and economic analysis (including network meta-analyses and health economic modeling), medical writing and publications, and AI-powered solutions. Its primary clients are top 10 pharmaceutical organizations, for whom it produces decision-grade evidence supporting health technology assessment (HTA) submissions, regulatory filings, market access planning, and post-approval evidence generation.

The firm operates a project-based, senior-scientist-led delivery model. The team comprises epidemiologists, biostatisticians, health economists, medical research scientists, and computer scientists, with all deliverables reportedly passing through the highest-ranked scientists before client release. Its AI-enabled evidence synthesis and SLR automation tools are positioned to accelerate screening, data extraction, and review workflows, while methodological rigor is established through peer-reviewed publications and conference presentations at ISPOR, ESMO, and ASCO. Client testimonials cite contributions to a Health Canada Special Need Drug Submission (SNDS) approval as evidence of regulatory-grade quality.

Commercially, Evidinno generates revenue through professional services engagements billed on a project basis under quote-driven contracts; no public pricing exists. Go-to-market relies on enterprise direct sales augmented by thought-leadership content (blog, publications, conference posters) and LinkedIn. As of January 5, 2026, Evidinno operates as a wholly owned subsidiary of United BioSource LLC (UBC) following an acquisition for which Fairmount Partners served as exclusive financial advisor, with the firm holding an Aboriginal or minority business enterprise certification under which over 70% of employees are recognized as visible minorities in Canada and the US.

Name

Evidinno Outcomes Research

Legal name

Evidinno Outcomes Research Inc.

Website

https://evidinno.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

11–50 employees

Short description

Evidinno Outcomes Research is a Vancouver-based healthcare research consulting firm delivering evidence synthesis, health economic modeling, HTA dossier development, and AI-enabled systematic literature reviews to top 10 pharmaceutical and biotechnology organizations worldwide.

Ownership category

akta.pro rank

Product category

Healthcare Research and HEOR Consulting

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK)

Keywords

• Health economics outcomes research
• Real-world evidence generation
• Health technology assessment
• Systematic literature reviews
• Pharmaceutical consulting services

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Research Consulting Services: Project-based consulting engagements delivering evidence synthesis, health economic analyses, and strategic research services to pharmaceutical clients. Services include literature reviews, statistical analysis, economic modeling, and medical writing for regulatory and HTA submissions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Evidinno Outcomes Research is a healthcare research consulting firm that delivers evidence-based solutions to pharmaceutical and biotechnology companies, spanning strategic consulting, systematic literature reviews, health economic modeling, network meta-analyses, medical writing, and AI-enabled evidence synthesis. Its services are designed to produce decision-grade real-world evidence for health technology assessment (HTA), regulatory submissions, and market access planning. Engagements are delivered as project-based consulting work by senior epidemiologists, biostatisticians, health economists, and medical research scientists.

Product overview

Evidinno Outcomes Research is a healthcare research consulting firm offering a portfolio of integrated services for real-world evidence generation, health economics, and outcomes research. The company operates five core service offerings: Strategic Consulting (providing evidence-based strategic guidance), Literature Reviews (systematic and comprehensive evidence synthesis), Complex Statistical & Economic Analysis (including network meta-analyses and health economic modeling), Medical Writing and Publications (manuscript and regulatory documentation), and AI-Powered Solutions (AI-enabled evidence synthesis and digital solutions). These services are designed to work together to deliver decision-grade evidence for health technology assessment, market access, and medical affairs planning for biopharmaceutical clients worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic Consulting Expert consulting providing strategic guidance on evidence generation, market access, and regulatory strategy for biopharmaceutical clients.
• Literature Reviews Comprehensive systematic literature reviews, meta-analyses, and evidence synthesis solutions for healthcare research and HTA submissions.
• Complex Statistical & Economic Analysis Advanced statistical analyses and health economic modeling services, including network meta-analyses, cost-effectiveness analyses, and economic evaluations.
• Medical Writing and Publications Medical writing services including publication planning, manuscript development, and regulatory documentation for peer-reviewed journals and conferences.
• AI-Powered Solutions AI-enabled evidence synthesis, literature review automation, and digital solutions leveraging artificial intelligence for healthcare research and evidence generation.

Quantifiable outcome

• Critical evidence contribution for Health Canada approval of SNDS (Special Need Drug Submission)

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

One partnership is on record.

• United BioSource LLC (UBC)coreStrategic or Co-development Partner · 5 January 2026United BioSource LLC (UBC) acquired Evidinno Outcomes Research Inc. on January 5, 2026. Evidinno operates as a wholly owned subsidiary within UBC, combining Evidinno's HTA- and regulatory-grade evidence synthesis, real-world evidence, and health economic capabilities with UBC's global evidence generation platform. The acquisition enhances UBC's analytical and synthesis capabilities in the high-stakes realm of reimbursement and regulatory decision-making.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Analysis Group: Analysis Group is a private economics and HEOR consulting firm that delivers economic modeling, RWE studies, and HTA support to biopharma. It is a direct peer in HEOR/RWE methods and biopharma customer base, though at significantly larger headcount.
• Cytel: Cytel provides biostatistics, statistical programming, and HEOR services including network meta-analysis and HTA support. It is highly comparable to Evidinno on the advanced statistical and economic analysis side, serving the same biopharma sponsor segment.
• Xcenda (Cencora/AmerisourceBergen): Xcenda is a market access and HEOR consulting arm of Cencora serving pharmaceutical manufacturers. It is a direct peer in HTA, value dossier, and RWE work, with a comparable customer base of top-10 pharma but at substantially larger scale.
• OPEN Health: OPEN Health combines HEOR, market access, medical communications, and RWE services for pharma. It directly competes with Evidinno in evidence synthesis and HTA dossier work, with broader integrated offerings and a global footprint.
• Putnam (Inizio Medical): Putnam, now part of Inizio Medical, is a HEOR and market access consultancy delivering evidence synthesis, economic modeling, and value communication for pharma. It competes with Evidinno across HTA submissions and payer engagement.
• Evidera (PPD/ICON): Evidera is a dedicated HEOR, RWE, and market access consulting business now part of ICON/PPD. It directly competes with Evidinno in HTA dossier development, network meta-analysis, and payer evidence generation for top-10 pharma, but at materially larger global scale.
• Precision AQ (Precision Value & Health): Precision AQ, formed from the merger of Precision Value & Health and Axtria's commercial services, provides HEOR, RWE, and market access services. It is a direct peer in HTA and payer evidence work for top pharma and biotech sponsors.

Emerging players

• PHMR (Pharmacoevidence / Valid Insight): PHMR and its sister brands are smaller HEOR/RWE consultancies offering systematic reviews, meta-analysis, and HTA support. They are emerging players with partial overlap to Evidinno's service mix, often competing on smaller pharma accounts.

Broad incumbents

• IQVIA (Real World Evidence): IQVIA operates a global RWE and HEOR practice that overlaps with Evidinno across evidence synthesis, economic modeling, and HTA submissions. It is a broad incumbent with far larger scale and a much wider service portfolio, competing primarily on enterprise program capacity.
• ICON plc (Commercial & Clinical Services): ICON, post-PRA Health and PPD acquisitions, is a top-tier global CRO with significant HEOR and market access capabilities. It is comparable to Evidinno in service offering (HEOR, RWE, HTA) but competes as a full-service incumbent rather than a focused specialty firm.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/evidinno

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evidinno Outcomes Research